twinter, it is not just you. The tier of the evidence has genuinely shifted in the last six months. That is a real and specific thing, not a perception artifact resulting from paying closer attention.
For anyone who wants the reasoning underneath that answer, here it is.
Six months ago the thesis was coherent and supported by meaningful but mixed evidence.
CCR5 was understood as an upstream trafficking coordinator. The CCL3/CCL4/CCL5 ligand system was documented. Leronlimab's anti-metastatic activity in TNBC was published in 2021 by Jiao, Wang, and Pestell. The PD-L1 upregulation finding from the Dolezal, Khan, and Lalezari case report existed. The hepatic fibrosis preclinical data existed in preprint form. The basic framework was coherent and had accumulated meaningful supporting evidence. But the tier at which that evidence existed was mixed: preclinical models, fragmented case reports, xenograft data, and inference from known receptor biology.
What has changed since then, is not the thesis. What has changed is the resolution and independence at which it is now being confirmed worldwide.
The CCR5+ CD8+ T cell exhaustion paper published May 30, 2026 confirmed the transcriptomic signature linking CCR5 expression on tumor-infiltrating CD8+ T cells to non-response to PD-1 blockade across multiple tumor types at single-cell resolution. Six months ago this relationship was inferred. It is now documented at the level the field requires before reorganizing clinical practice around a new target. Single-cell transcriptomics is not an incremental upgrade; it is a qualitative shift in the specificity and interpretability of the evidence.
The Mendelian Randomization proof in Crohn's disease published June 2026 moved the CCL3-CCR5 axis from correlation to causality in a chronic inflammatory disease completely outside the oncology literature, using germline genetic variants as natural experiments not mixed up by tumor biology or treatment history. Six months ago the CCR5 relevance in IBD was known from preclinical colitis models. It is now proven to be causal in humans through a methodology the field treats as the closest available approximation to a randomized controlled trial in observational data.
The Frontiers in Immunology phosphoproteomics paper from June 2, 2026 established that CCR5 knockout completely abolishes CEP131, KHDRBS1, and MAPK6 activation in melanoma cells. Six months ago the proliferative role of CCR5 in tumor cells was hypothesized from receptor biology. It is now documented at the kinase substrate level in a peer-reviewed phosphoproteomics study.
At AACR Annual Meeting in April, Dr. Kasi reported that among pre-screened CLOVER patients with evaluable samples, CCR5 expression was detected in 100 percent of cases. Not ninety-five percent. One hundred percent in the screened mCRC population.
The SALIENT-AD trial dosing its first patient on June 11 at Weill Cornell is new. The Natera collaboration announced June 4 is new. Patent 12,624,111 issued May 12 is new. The Palmer hepatic fibrosis paper moving from preprint to peer-reviewed publication is new in its confirmation status even though the underlying data existed earlier.
The architecture was always there. What has changed is the resolution at which it is now visible and the independence of the laboratories who confirm it. Six months ago the thesis was very compelling. Today it is documented at single-cell resolution, proven causal through Mendelian Randomization, confirmed at the phosphoprotein level, and validated by investigators at institutions with no commercial relationship to this company across four separate disease verticals simultaneously.
That is a real shift. You identified it correctly.
For anyone who wants the reasoning underneath that answer, here it is.
Six months ago the thesis was coherent and supported by meaningful but mixed evidence.
CCR5 was understood as an upstream trafficking coordinator. The CCL3/CCL4/CCL5 ligand system was documented. Leronlimab's anti-metastatic activity in TNBC was published in 2021 by Jiao, Wang, and Pestell. The PD-L1 upregulation finding from the Dolezal, Khan, and Lalezari case report existed. The hepatic fibrosis preclinical data existed in preprint form. The basic framework was coherent and had accumulated meaningful supporting evidence. But the tier at which that evidence existed was mixed: preclinical models, fragmented case reports, xenograft data, and inference from known receptor biology.
What has changed since then, is not the thesis. What has changed is the resolution and independence at which it is now being confirmed worldwide.
The CCR5+ CD8+ T cell exhaustion paper published May 30, 2026 confirmed the transcriptomic signature linking CCR5 expression on tumor-infiltrating CD8+ T cells to non-response to PD-1 blockade across multiple tumor types at single-cell resolution. Six months ago this relationship was inferred. It is now documented at the level the field requires before reorganizing clinical practice around a new target. Single-cell transcriptomics is not an incremental upgrade; it is a qualitative shift in the specificity and interpretability of the evidence.
The Mendelian Randomization proof in Crohn's disease published June 2026 moved the CCL3-CCR5 axis from correlation to causality in a chronic inflammatory disease completely outside the oncology literature, using germline genetic variants as natural experiments not mixed up by tumor biology or treatment history. Six months ago the CCR5 relevance in IBD was known from preclinical colitis models. It is now proven to be causal in humans through a methodology the field treats as the closest available approximation to a randomized controlled trial in observational data.
The Frontiers in Immunology phosphoproteomics paper from June 2, 2026 established that CCR5 knockout completely abolishes CEP131, KHDRBS1, and MAPK6 activation in melanoma cells. Six months ago the proliferative role of CCR5 in tumor cells was hypothesized from receptor biology. It is now documented at the kinase substrate level in a peer-reviewed phosphoproteomics study.
At AACR Annual Meeting in April, Dr. Kasi reported that among pre-screened CLOVER patients with evaluable samples, CCR5 expression was detected in 100 percent of cases. Not ninety-five percent. One hundred percent in the screened mCRC population.
The SALIENT-AD trial dosing its first patient on June 11 at Weill Cornell is new. The Natera collaboration announced June 4 is new. Patent 12,624,111 issued May 12 is new. The Palmer hepatic fibrosis paper moving from preprint to peer-reviewed publication is new in its confirmation status even though the underlying data existed earlier.
The architecture was always there. What has changed is the resolution at which it is now visible and the independence of the laboratories who confirm it. Six months ago the thesis was very compelling. Today it is documented at single-cell resolution, proven causal through Mendelian Randomization, confirmed at the phosphoprotein level, and validated by investigators at institutions with no commercial relationship to this company across four separate disease verticals simultaneously.
That is a real shift. You identified it correctly.
27
